US Regulators Say Current COVID Vaccines Not ‘Well-Matched’ Against BA.2 Subvariant

US Regulators Say Current COVID Vaccines Not ‘Well-Matched’ Against BA.2 Subvariant
A nurse prepares the Pfizer-BioNTech COVID-19 vaccine in a file image. Jeff Kowalsky/AFP via Getty Images
Zachary Stieber
Zachary Stieber
Senior Reporter
|Updated:
0:00

The three COVID-19 vaccines authorized for use in the United States are not “well-matched” against the BA.2 virus subvariant, which has recently been estimated to have become dominant in the country, U.S. regulators said on April 6.

“While currently available vaccines are not well-matched to the dominant circulating variant—which is the Omicron BA.2 sublineage—we do still have some residual vaccine effectiveness,” particularly against severe outcomes, Dr. Dorian Fink, an official with the Food and Drug Administration (FDA), said.

Zachary Stieber
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
twitter
truth
Related Topics